Advertisement

Topics

Latest "Cyclica" News Stories

13:12 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Cyclica" found in our extensive news archives from over 250 global news sources.

More Information about Cyclica on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cyclica for you to read. Along with our medical data and news we also list Cyclica Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cyclica Companies for you to search.

Showing "Cyclica" News Articles, all 16

Tuesday 22nd January 2019

AAIH Announces Inaugural Board of Directors and Officers After Formal Launch

The Alliance for Artificial Intelligence in Healthcare (AAIH) announced today that it has formally launched after the inaugural meeting of its 22-person Board of Directors. During the inaugural meeting held on January 9 in San Francisco at Amazon Web Services, the Board appointed the following Executive Officers: John Baldoni, former Senior Vice P...


Wednesday 12th December 2018

Merck KGaA takes ‘balanced risk’ with Cyclica’s AI platform

Merckâs agreement with Cyclica will establish efficiency in its small molecule therapy development with access to Cyclicaâs AI protein screening platform.

Monday 10th December 2018

Merck KGaA links with AI firm to iron out side-effects during R&D

Germany’s Merck KGaA has begun a licensing agreement with Canadian pharma R&D company Cyclica using artificial intelligence (AI) to uncover new drug targets and predict any side effects. Cyclica has a cloud-based technology that screens small ...


Sunday 9th December 2018

Merck partners with Cyclica for AI-based screening of drug targets

Merck has signed an agreement to licence Canadian Cyclica’s cloud-based in-silico proteome screening platform called Ligand Express to support its...Read More... The post Merck partners with Cyclica for AI-based screening of drug targets appeared first on Pharmaceutical Technology.

Thursday 6th December 2018

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK- Agreement to screen discovery and early development compounds using artificial intelligence and computa...

Merck KGaA in Agreement for AI-Augmented Screening Platform to Expand Research Capabilities

NewsThe agreement with Cyclica Inc. will enable Merck KGaA to quickly elucidate mechanisms of action, evaluate safety profiles, and explore additional applications for a number of its investigational small molecules.

Merck KGaA, Cyclica in AI Screening Platform Pact

Augmented platform is being used to uncover novel targets that are modeled to interact with a small molecule

Wednesday 28th November 2018

Bayer taps AI technologies in drug discovery collaboration

Cyclica, a Bayer G4A company, will work with Bayer to advance drug discovery. The collaboration will involve looking further into polypharmacological profiles of small molecules.

Tuesday 27th November 2018

Cyclica, Bayer partner to advance drug discovery programs

The companies will advance drug discovery programs by gaining insights into the polypharmacological profiles of small molecules, while further evolving Cyclica’s integrated network of enabling technologies. Through a The post Cyclica, Bayer partner to advance drug discovery programs appeared first on Pharmaceutical Business review.

Monday 26th November 2018

Cyclica Drives Drug Discovery Through AI-Augmented Integrated Network of Cloud-Based Technologies together with Bayer

Cyclica (www.cyclicarx.com), a Bayer G4A company is pleased to announce a collaboration with Bayer to advance drug discovery programs by gaining insights into the polypharmacological profiles of small molecules, while further evolving Cyclica’s integrated network of enabling technologies.

Wednesday 24th October 2018

Cyclica’s Cloud-Based Platform, Ligand Express, Will Help New Discovery Efforts in Bioactive Products for the National Research Council (NRC) of Canada

Cyclica is pleased to announce that, through the Build in Canada Innovation Program (BCIP), a team of scientists from the National Research Council of Canada (NRC) will have access to Ligand Express—Cyclica’s cloud-based platform. Accessing Ligand Express will help advance new discovery efforts at the NRC, particularly in naturally occurring b...

Cyclica’s Cloud-Based Platform, Ligand Express, Will Help New Discovery Efforts in Bioactive ...

Cyclica Inc.Naheed KurjiPresident and CEOnaheed.kurji@cyclicarx.com Read more...

Wednesday 12th September 2018

Alliance for Artificial Intelligence in Healthcare (AAIH) Convenes in Boston and Basel to Announce Mission and Launch Activities

Leaders in AI for Healthcare applications have come together to form a global organization to educate and advocate for policies and regulations to promote rapid integration and utilization of AI in healthcare The founding members of the Alliance for Artificial Intelligence in Healthcare (AAIH) met on September 6th during Boston Biotech Week (Bos...

Monday 27th August 2018

WuXi AppTec and Cyclica team to drive polypharmacology in drug discovery

The multi-phase collaboration between WuXi AppTec Research Service Division and Cyclica looks to advance polypharmacology in drug discovery using AI-augmented technology.

Friday 17th August 2018

WuXi AppTec, Cyclica collaborate to advance drug discovery programs

Through a multi-phase collaboration, WuXi will leverage and evaluate Cyclica’s cloud-based proteome Ligand Express screening platform to investigate the off-target profiles of small molecules, apply Cyclica’s novel and The post WuXi AppTec, Cyclica collaborate to advance drug discovery programs appeared first on Pharma Business review.

Thursday 16th August 2018

WuXi AppTec Research Service Division and Cyclica Collaborate to Drive Polypharmacology in Drug Discovery Through AI-Augmented Technologies

WuXi AppTec Research Service Division (www.wuxiapptec.com), and Cyclica (www.cyclicarx.com) are pleased to announce a multi-phase collaboration to advance drug discovery programs


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks